Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.

Employees

596

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/10/26	HK$21.32	+1.43%	73,400
13/10/26	HK$21.02	+1.06%	73,700
12/10/26	HK$20.80	+0.19%	72,500
09/10/26	HK$20.76	+0.48%	71,800
08/10/26	HK$20.66	-0.58%	70,800

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

17.93CNY

Average target price

19.66CNY

Spread / Average Target

+9.69%

Consensus

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Medtide Inc.

Company calendar

Market Closed - Hong Kong S.E. 16:08:26 14/10/2026 HKT			5-day change	1st Jan Change
21.32 ^HKD	+1.43%		+2.60%	-30.05%

09-24	Medtide Acquires China Land, Property for Peptide CDMO Project	MT
09-24	Medtide Inc. Announces Resignation of Li Lingmei as Executive Director, Effective September 24, 2026	CI

Market Cap	2.54B 2.98B 380M 339M 316M 287M 540M 36.05B 544M 3.79B 1.48B 18.75B 1.43B 1.39B 60.16B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	1.96B 2.3B 293M 262M 244M 221M 417M 27.84B 420M 2.93B 1.15B 14.48B 1.1B 1.08B 46.46B	EV / Sales 2026 *	3.28x	EV / Sales 2027 *	2.55x
Free-Float	19.48%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Hong Kong S.E.	3880	Delayed
Deutsche Boerse AG	FQ2	Delayed

09-24	Medtide Acquires China Land, Property for Peptide CDMO Project	MT
09-24	Medtide Inc. Announces Resignation of Li Lingmei as Executive Director, Effective September 24, 2026	CI
09-21	Medtide Inc.(SEHK:3880) added to S&P Global BMI Index	CI
08-27	Medtide Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-31	Medtide Names CFO	MT
07-31	Medtide Inc. Announces Appointment of Ding Lijun as Chief Financial Officer, Effective July 31, 2026	CI
07-31	Medtide Inc. Announces Management Changes, Effective July 31, 2026	CI
07-31	Medtide Inc. Announces Change of Principal Place of Business in Hong Kong	CI
07-31	Medtide Inc. Provides Group Earnings Guidance for the Six Months Ended Year Ended June 30, 2026	CI
06-30	95,524,875 H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 29-JUN-2026.	CI
06-18	Medtide Inc. Announces Abolishment of the Supervisory Committee	CI
03-31	Medtide Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-09	Medtide Completes Hong Kong-Listed Share Full Circulation	MT

Medtide Inc. Stock

Stocks

3880

CNE100006S86

Biotechnology & Medical Research

Valuation: Medtide Inc.

Chart: Medtide Inc.

Latest news: Medtide Inc.

Press Releases: Medtide Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Medtide Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Net sales - Rate of surprise

1 day	+1.43%
1 week	+2.60%
Current month	-0.93%
1 month	+13.04%
3 months	-11.54%
6 months	-4.39%
Current year	-30.05%

1 week	20.28	21.48
1 month	18.42	23.8
Current year	17.64	30.46
1 year	17.64	31.98
3 years	17.64	41.72
5 years	17.64	41.72
10 years	17.64	41.72

Manager	Title	Age	Since
Qi Xu CEO	Chief Executive Officer	58	11/06/2020
Li Jun Ding DFI	Director of Finance/CFO	50	31/07/2026
Wei Qun Xu DFI	Director of Finance/CFO	53	01/10/2020

Director	Title	Age	Since
Qi Xu CHM	Chairman	58	11/06/2020
Xiang Li Li BRD	Director/Board Member	51	27/01/2022
Xiang Li BRD	Director/Board Member	63	27/01/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/3/26	Qi Xu	Other	Chief Executive Officer	68,201,112	48.0967%
9/3/26	Xiang Li Li	Other	Director	68,201,112	48.0967%
9/3/26	Qi Xu	Other	Chief Executive Officer	68,201,112	48.0967%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MEDTIDE INC.	+1.43%	+2.60%	-30.33%	-	380M
WUXI APPTEC CO., LTD.	-0.32%	-5.97%	+57.78%	+74.48%	70.44B
ARGENX SE	+0.75%	-13.64%	+5.38%	+54.09%	50.31B
LONZA GROUP AG	+2.79%	+1.07%	+11.46%	+36.92%	47.51B
IQVIA HOLDINGS INC.	-0.58%	+0.27%	+27.93%	+30.76%	42.91B
REVOLUTION MEDICINES, INC.	-2.84%	-5.72%	+286.54%	+530.02%	40.39B
BEONE MEDICINES AG	-0.38%	-3.78%	+6.74%	+95.25%	39.69B
CELLTRION, INC.	-0.39%	-1.48%	+10.41%	+43.19%	30.59B
WUXI BIOLOGICS (CAYMAN) INC.	-2.95%	-12.28%	+43.51%	+1.51%	26.8B
BIONTECH SE	-7.13%	-7.02%	-12.99%	-14.07%	22.36B
Average	-0.96%	-4.88%	+40.64%	+94.68%	37.14B
Weighted average by Cap.	-0.69%	-5.60%	+51.45%	+100.48%

	2026 *	2027 *
Net sales	599M 702M 89.43M 79.88M 74.46M 67.51M 127M 8.49B 128M 892M 349M 4.41B 336M 328M 14.17B	742M 870M 111M 99.06M 92.33M 83.71M 158M 10.53B 159M 1.11B 433M 5.47B 416M 407M 17.57B
Net income	-	-
Net Debt	-579M -679M -86.49M -77.26M -72.02M -65.29M -123M -8.21B -124M -863M -338M -4.27B -325M -318M -13.7B	-649M -761M -96.95M -86.61M -80.73M -73.19M -138M -9.2B -139M -967M -379M -4.79B -364M -356M -15.36B